Cencora (WBO:ABC) YoY EBITDA Growth: 13.17% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:ABC Cencora Inc WBO:ABC
68 GF Score
Price €278.90
GF Value €271.59
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Cencora YoY EBITDA Growth?

Cencora WBO:ABC 68 YoY EBITDA Growth is 13.17% as of Jun. 2026. GuruFocus rates WBO:ABC with a GF Score™ of 68/100 and a GF Value™ of €271.59 (Fairly Valued). The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Cencora's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 13.17%.

Cencora's EBITDA per Share for the three months ended in Jun. 2026 was €6.39.

Cencora YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Cencora's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cencora YoY EBITDA Growth Chart

Cencora Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 160.29 25.05 4.02 -1.75 7.81

Cencora Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.65 -61.08 -1.06 76.60 13.17
WBO:ABC
68GF Score
Cencora Inc WBO:ABC
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cencora YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Cencora's YoY EBITDA Growth for the fiscal year that ended in Sep. 2025 is calculated as:

YoY EBITDA Growth (A: Sep. 2025 )
=(EBITDA per Share (A: Sep. 2025 )-EBITDA per Share (A: Sep. 2024 ))/ | EBITDA per Share (A: Sep. 2024 ) |
=(16.351-15.167)/ | 15.167 |
=7.81 %

Cencora's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(6.393-5.649)/ | 5.649 |
=13.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 13.17% mean?
Cencora (WBO:ABC) has a YoY EBITDA Growth of 13.17% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cencora and its competitors.
Is Cencora's YoY EBITDA Growth too high?
Cencora's current YoY EBITDA Growth is 13.17%. Overall, Cencora has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cencora's YoY EBITDA Growth compare to CAH and MCK?
Cencora's YoY EBITDA Growth of 13.17% can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Distribution company?
A good YoY EBITDA Growth depends on the Medical Distribution industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Cencora and its competitors. Cencora's current YoY EBITDA Growth is 13.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cencora stock overvalued right now?
Based on GuruFocus' analysis, Cencora (WBO:ABC) is currently considered Fairly Valued. The stock's GF Value™ is €271.59, compared to a current price of €278.90 — trading 2.7% above its estimated fair value. The current YoY EBITDA Growth is 13.17%. Cencora's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Cencora (WBO:ABC), the current YoY EBITDA Growth is 13.17% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cencora (WBO:ABC) Overvalued in 2026?

Based on GuruFocus' analysis, Cencora stock appears to be overvalued. The current stock price of €278.90 is trading 2.7% above its estimated GF Value™ of €271.59. GuruFocus considers Cencora to be Fairly Valued.

Key valuation signals for WBO:ABC:

  • YoY EBITDA Growth: 13.17%
  • GF Value™: €271.59 vs. price of €278.90 (2.7% above fair value)
  • GF Score™: 68/100 with 2 warning signs

No single metric tells the full story. See the WBO:ABC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cencora Business Description

Address 1 West First Avenue, Conshohocken, PA, USA, 19428-1800
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
68GF Score

Get the complete analysis for WBO:ABC

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€278.90
Price
€271.59
GF Value